$591 | SAVE $104 | Single User
$2423 | SAVE $427 | Site License
$4803 | SAVE $847 | Global License

The Rise of Health Outcome Liaison Teams

The Rise of Health Outcome Liaison Teams
[Lowest Price Guaranteed: $591]

Published by FirstWord Pharma: 01 Nov 2012 | 30 | In Stock
Related Topics: Exploration , Pharmaceuticals

Introduction

Introduction


When it comes to market access, the payers hold the cards. However, in recent years, pharma companies in the US and Europe have found that a Health Outcome Liaison resource has helped evolve a transactional, often distrustful, relationship to one that is much more collaborative.


As HOLs become more established, payers are increasingly receptive to sharing data and commissioning research, with a united goal of improving not only clinical outcomes, but also patient outcomes – through quality improvement and measurement.


However, the rise of HOLs has happened so fast that many companies lack a clear understanding of the HOL role. What does an HOL do? What are the key qualifications? How do HOLs relate to MSLs? And where should they be located within the organisation?


FirstWord’s new HOL report is designed to help pharma companies answer these critical questions.


Scope


Report Overview


The Rise of Health Outcome Liaison Teams


At last – a practical guide to building your Health Outcome Liaison team and developing an effective HOL strategy.


This comprehensive report explains what is driving the rise of HOLs globally, and provides detailed accounts of how major pharma companies are interpreting the evolving HOL role.


The report draws on exclusive insights from experts who are truly in the trenches of HOL management, both in-house and outsourced. Through their experiences and expertise, you’ll learn best practices for recruiting and retaining HOL talent, effective Health Outcomes Data usage, and ultimately building mutually beneficial relationships with payers.


For a complete understanding of how HOLs can strengthen your organisation, don’t miss this essential report.


Highlights


Key Report Features


  • Insights from experts dealing with HOL teams and issues at ground level, in the US and Europe

  • Study of the market drivers for HOL teams, now and in the future

  • Definitions, qualifications, and functions of Health Outcome Liaisons

  • Management and organisation of HOL teams: budgeting, reporting lines, career paths, etc.

  • Detailed examination of Health Outcome Data trends and best practices

  • Exploration of potential HOL compliance issues, and how to avoid them

  • Puchase Reasons


    Key Benefits


  • Learn about the drivers of demand for Health Economics and Outcomes Research (HEOR) data and why HOL teams are being set up in the US and Europe

  • Know what kinds of data are needed by payers and health technology assessment bodies to substantiate product value and help achieve better health outcomes at a manageable cost

  • Understand how data needs to be tailored to in-market conditions, product/therapeutic category specifics (including competition), and varying demand between countries, regions, customers, and local health economies

  • Discover ways that HOL teams can work in partnership with payers/HTA bodies to mutual benefit

  • Find out what skills and qualifications make up an effective HOL team, and how these qualities can be nurtured for the long term

  • Be aware of potential compliance issues around HOL teams if their identity and functions are not properly delineated within a wider market-access framework


  • Key Questions Answered


  • Should we have an HOL team, and if so, should it be in-house or outsourced?

  • What qualifications and personal qualities should I look for in an HOL?

  • How do HOLs fit into our broader market strategy?

  • Who should the HOL team report to?

  • What are the current demands for outcomes data and best practices for meeting those needs?

  • How can we use our HOL team more effectively?

  • How can I ensure that overlaps between HOL and other market-access functions, especially MSLs, don’t lead to ambiguity or compliance issues?

  • At what point in the product lifecycle should the HOL team get involved?

  • How can I attract and retain optimal HOL personnel?

  • Who Should Read This Report


  • HOL team leaders

  • Market access directors

  • Sales and marketing directors

  • Executive-level pharmaceutical management

  • Health technology assessors, payers, and budget holders

  • Expert Views Include:


    Tim Birner, senior director, Health Outcomes and Pharmacoeconomics, Endo Pharmaceuticals


    Joechen Fleischman, head of market access, Janssen, Germany


    Janice Haigh, practice leader, Market Access Europe, Quintiles


    Chad Patel, senior field manager, Health Economics and Outcomes Research, Astellas Pharma, US


    Gareth Williams, director, UK Market Access, Quintiles


    Robin Winter-Sperry, MD, president and chief executive officer, Scientific Advantage


    Key Quotes


    “Everyone has to find ways to improve outcomes, focusing on quality improvement, quality measurement …. As long as you can brief them with that information – not just with products but health policy, the business – they are open to see you a bit more.” Chad Patel, senior field manager, health economics and outcomes research, Astellas Pharma US


    “There are still people in pharma companies who think their customer is the doctor and all this other stuff is here to solve a problem they have with reaching doctors. In my mind, all these people out there working in teams to organize care for the local population, they are all our customers, and it’s the job of any company to understand the customer.” Janice Haigh, practice leader, market access Europe, Quintiles


    “If you’ve got an experienced team, they know how to build the relationships. You can start earlier and have a strong level of transfer into those relationships if you’re not rolling the temporary people into full-time people.” Dr. Robin Winter-Sperry, president and chief executive officer, Scientific Advantage

    Table of Contents
    for The Rise of Health Outcome Liaison Teams

    • 1. Market access: the payers hold the cards

      1.1. Engaging in the outcomes debate

      1.2. Long-term and global

      1.3. At their own pace

      2.What are Health Outcomes Liaisons?

      2.1. Evolutionary state

      2.2. HOL teams are growing

      2.3. More title than function

      3. In-house or outsourced?

      3.1. Store of expertise

      3.2. Layer of credibility

      3.3. Retaining intellectual capital

      4.The What, How and When of Health Outcomes Data

      4.1. A broad church

      4.2. The demand for data

      4.3. It’s all relative

      4.4. Exceptional differentiation

      4.5. Local affordability

      4.6. Service and support

      4.7. Changing pathways

      4.8. Make it meaningful

      4.9. Pre-approval phase

      4.10. Head-to-head

      4.11. Resource use

      4.12. Payer receptivity

      4.13. A credible conversation

      4.14. When to deliver

      4.15. R&D input

      4.16. Maintaining access

      4.17. Laying the groundwork

      4.18. A real-world negotiation

      5. Who are we talking to?

      5.1. Demarcation counts

      5.2. Doing it for themselves

      6. Building the HOL team

      6.1. You want some uniqueness

      6.2. Corporate values

      6.3. How they operate

      7.Budgeting, reporting

      7.1. Favourable climate

      7.2. Lines and boundaries

      7.3. Ninety-eight per cent scientific

      7.4. Overlapping roles

      7.5. Different environment

      7.6. Staying compliant

      7.7. Specific guidance

      8.What next for HOLs?

      8.1. Way to go

      8.2. Deeper relationships

      8.3. Career paths

      8.4. Managers of the future

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    30 |

    Number of Pages

    86

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! The Rise of Pet and Plant Parents - Coronavirus (COVID-19) Consumer Behavior Impact
    The Rise of Pet and Plant Parents - Coronavirus (COVID-19) Consumer Behavior ImpactSummaryThis repor...
    16 Jul 2020 by Global Data USD $1,233 (normally
    USD $1,451)
    More Info
    SAVE 15% today! RISE Life Science Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
    RISE Life Science Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Repor...
    28 Jul 2018 by Marketline USD $298 (normally
    USD $351)
    More Info
    SAVE 15% today! Global and Chinese High - rise Commercial Elevator Industry, 2017 Market Research Report
    The 'Global and Chinese High - rise Commercial Elevator Industry, 2012-2022 Market Research Report' ...
    18 Dec 2017 by Prof Research USD $2,550 (normally
    USD $3,000)
    More Info
    SAVE 15% today! Global and Chinese High-rise Commercial Elevator Industry, 2017 Market Research Report
    The 'Global and Chinese High-rise Commercial Elevator Industry, 2012-2022 Market Research Report' is...
    18 Dec 2017 by Prof Research USD $2,550 (normally
    USD $3,000)
    More Info
    SAVE 15% today! Global and Chinese High-rise Elevator Industry, 2017 Market Research Report
    The 'Global and Chinese High-rise Elevator Industry, 2012-2022 Market Research Report' is a professi...
    18 Dec 2017 by Prof Research USD $2,550 (normally
    USD $3,000)
    More Info
    SAVE 15% today! Global and Chinese High-rise Residential Elevator Industry, 2017 Market Research Report
    The 'Global and Chinese High-rise Residential Elevator Industry, 2012-2022 Market Research Report' i...
    18 Dec 2017 by Prof Research USD $2,550 (normally
    USD $3,000)
    More Info
    SAVE 15% today! Global and Chinese Low-rise Elevator Industry, 2017 Market Research Report
    The 'Global and Chinese Low-rise Elevator Industry, 2012-2022 Market Research Report' is a professio...
    18 Dec 2017 by Prof Research USD $2,550 (normally
    USD $3,000)
    More Info
    SAVE 15% today! Global and Chinese Low-rise Residential Elevator Industry, 2017 Market Research Report
    The 'Global and Chinese Low-rise Residential Elevator Industry, 2012-2022 Market Research Report' is...
    18 Dec 2017 by Prof Research USD $2,550 (normally
    USD $3,000)
    More Info
    SAVE 15% today! The Rise of Wearable Healthcare Technology: Opportunities and Challenges for Pharma
    IntroductionIn The Rise of Wearable Healthcare Technology: Opportunities and Challenges for Pharma, ...
    01 Feb 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    The Rise of Health Outcome Liaison Teams | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...